The protein p53 suppresses tumor development by inducing tumor cell death. However, targeting p53 for the treatment of cancer is confounded by the fact that genetic mutations cause loss or inactivation of p53 in approximately 50 percent of human cancers. Now, a new study indicates that targeting the p53-related protein p73 in mice induces the regression of established tumors of human origin, leading to the suggestion that p73 might be a viable target for developing anticancer therapeutics.
More...
Linear Mode
